Bivision Pharmaceuticals(Shanghai),Inc. (hereinafter referred to as "Bivision") recently announced that its independently developed novel targeted radiopharmaceutical has successfully completed the first patient dosing in Phase I clinical trial. The trial aims to evaluate the safety, pharmacokinetics, and anti-tumor activity in patients with advanced prostate cancer.

About Targeted radiopharmaceutical therapy

Targeted radiopharmaceutical therapy is emerging as a safe and effective targeted approach to treating many types of cancer. In targeted radiopharmaceutical therapy, radiation is systemically or locally delivered using pharmaceuticals that either bind preferentially to cancer cells or accumulate by physiological mechanisms. This approach can achieve the integration of imaging and therapy with the use of corresponding isotopes.

About Bivision

Founded in 2021, Bivision is an innovative biotech company committed to develop the next generation of targeted radionuclide therapy (TRT). Bivision was founded by a group of biotech veterans who have extensive experience and track record in the field of targeted radionuclide therapy. Their hands-on experience and vision to develop new radiopharmaceuticals build up a solid foundation for Bivision to plan and execute its TRT drug discovery and development projects. Since its inception, the key proprietary technology platforms for nuclear drug development were built in the aspect of ligand screening, linker conjugation (J-Linker technology) and clinical transformation. The synchronous development and effective integration of these platforms are the core driving force for the rapid advancement of the product pipeline. The company's first drug candidate is under Phase I clinical evaluation.